U.S., Sept. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07793903) titled 'BCT301 in Treating Refractory/Recurrent IgG4-related Disease' on Aug. 16.
Brief Summary: This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
IgG4-related Disease
Intervention:
OTHER: BCT301 Cell Injection
BCT301 Cell Injection are CAR-iT cells derived from chemically induced pluripotent stem cells. Six subjects with refractory/recurrent IgG4-RD meeting the inclusion/exclusion criteria a...